These authors demonstrated that the continual expression of the EGFR mutant is not only essential for tumor development but also for tumor stability, and that EGFR-targeted therapy for EGFR-mutated lung adenocarcinoma is dramatically effective, suggesting that EGFR mutants are directly involved in tumor maintenance. This evidence concerns the gene EGFR and lung adenocarcinoma.